These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36780236)

  • 1. Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.
    Jin P; Li X; Xia Y; Li H; Li X; Yang ZY; Wang Z; Xu C; Fang T; Zhou D; Xiong X; Wang SY; Xu S; Gao Q
    Mol Cancer Ther; 2023 Apr; 22(4):447-458. PubMed ID: 36780236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.
    Li X; Fang T; Xu S; Jin P; Zhou D; Wang Z; Li H; Yang Z; Chen G; Zheng X; Xia Y; Wei X; Zhang Z; Yang X; Wang Y; Gao Q
    NPJ Precis Oncol; 2021 Jun; 5(1):49. PubMed ID: 34108603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
    Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibitors in Ovarian Cancer: A Review.
    O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
    Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    Yanaihara N; Yoshino Y; Noguchi D; Tabata J; Takenaka M; Iida Y; Saito M; Yanagida S; Iwamoto M; Kiyokawa T; Chiba N; Okamoto A
    Gynecol Oncol; 2023 Jan; 168():83-91. PubMed ID: 36403366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
    Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling PARP inhibitor resistance.
    Fugger K; Hewitt G; West SC; Boulton SJ
    Trends Cancer; 2021 Dec; 7(12):1102-1118. PubMed ID: 34563478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
    Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer.
    Deng O; Dash S; Nepomuceno TC; Fang B; Yun SY; Welsh EA; Lawrence HR; Marchion D; Koomen JM; Monteiro AN; Rix U
    J Biol Chem; 2022 Nov; 298(11):102550. PubMed ID: 36183837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
    Huang TT; Burkett SS; Tandon M; Yamamoto TM; Gupta N; Bitler BG; Lee JM; Nair JR
    Oncogene; 2022 Nov; 41(46):5020-5031. PubMed ID: 36224341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
    Washington CR; Moore KN
    Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired
    Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
    Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    Smith M; Pothuri B
    Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition.
    Jamal K; Galbiati A; Armenia J; Illuzzi G; Hall J; Bentouati S; Barrell D; Ahdesmäki M; ; O'Connor MJ; Leo E; Forment JV
    Cancer Res Commun; 2022 Oct; 2(10):1244-1254. PubMed ID: 36969741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.